TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01073189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-Renal Fenoldopam
Description: Placement of an intra-renal catheter for infusion of fenoldopam mesylate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Patients randomized to the Diuretic Control group will receive intravenous furosemide as an active control
Study: NCT02997514

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Solution Focused Coaching
Description: SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Solution Focused Coaching
Description: Intensive SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
Study: NCT00857246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study: NCT02212418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal hypopressive technique
Description: postural technique based on self-elongating, body axis anteriorization, shoulders extension, and maintenance of an expiratory apnea as long as possible
Study: NCT02438930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention during HIV testing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care counseling during HIV testing
Study: NCT00739128

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis B vaccine (EngerixB)
Description: A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscular at zero, one and six months intervals

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis B vaccine (EngerixB)
Description: A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intradermally in the deltoid region at zero, one and six months intervals
Study: NCT04453644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle static stretching
Description: On day-I: Static Stretching done for 2 minutes (SS2), on day-II: Static Stretching done for 4 minutes (SS4), and on day-III: Static Stretching done for 8 minutes (SS8).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle static stretching
Description: On day-I: Static Stretching done for 2 minutes (SS2), on day-II: Static Stretching done for 4 minutes (SS4), and on day-III: Static Stretching done for 8 minutes (SS8).
Study: NCT01237470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Desarda technique
Description: no mesh technique with undetached strip of external oblique aponeurosis placed at the floor of inguinal canal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein technique
Description: hernioplasty with the usage of plain polypropylene mesh
Study: NCT03789409

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: The aforementioned intermittent fasting in arm/group descriptions.
Study: NCT02986451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.
Study: NCT04452838

Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine BIC SR4 fed (Treatment E in Part B)
Description: 4 mg administered under fed conditions
Study: NCT04481659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lap partial ISR
Description: A direct laparoscopic surgery with completely abdominal approach laparoscopic partial intersphincteric resection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NCRT+Lap partial ISR
Description: Preoperative radiation and chemotherapy + laparoscopic completely abdominal approach laparoscopic partial intersphincteric resection
Study: NCT00611156

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ginger
Description: added to a brunch meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: black pepper
Description: Added to a brunch meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: horseradish
Description: Added to a brunch meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mustard
Description: Added to a brunch meal
Study: NCT02986451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle
Study: NCT00597805

Intervention type: BEHAVIORAL
Intervention: questionnaires/interviews
Description: All patients who agree to participate will be interviewed for a baseline quality of life assessment prior to surgery. A brief in hospital interview will follow in the peri-operative period. In the ensuing months, patients will be interviewed at approximately 3, 6 and 12 months post-operatively (eg: 3 month interview will be done between 8-16 weeks and 6 month interview between 20-28 months post-operatively). Annual interviews in years two through five will be employed to determine areas for future study and solicit narrative on transition toward cancer survivorship.
Study: NCT01794403

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Extended Hypofractionation Radiotherapy
Description: A total dose of 70.2 Gy will be delivered in 26 fractions, 2.7 Gy to the Planning Target Volume (PTV) by Intensity Modulated Radiotherapy (IMRT) with stationary gantry or rotating gantry technique.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Hypofractionation Radiotherapy
Description: A total dose of 36.25 Gy will be delivered in 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV), by Stereotactic Body Radiotherapy (SBRT) techniques.
Study: NCT03322267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Cisplatin (30 mg/m2, QW, 2 cycles) and radiotherapy (18-26 Gy/10-13 fractions) as adjuvant chemoradiotherapy, followed by pembrolizumab (200mg, Q3W, 18 cycles)
Study: NCT03651739

Intervention type: DEVICE
Intervention: Knee Connect
Description: An electronic goniometer with smart phone application
Study: NCT01756326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PREOB® Implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Autograft
Study: NCT03927300

Intervention type: DEVICE
Intervention: Telemonitoring Software
Description: Recovery of retrospective data in dialysis patients follow or not follow by a telemonitoring application.
Study: NCT00859105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5%: manufactured by Apotex
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adara 5% Cream US
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adara 5% Cream Canada
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Imiquimod Vehicle
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
Study: NCT02486081

Intervention type: DEVICE
Intervention: smart soccer ball
Description: smart soccer ball was used to measure participant's performance in total time and distance for completion, and acceleration

Intervention type: DEVICE
Intervention: smart soccer ball
Description: smart soccer ball was used to measure participant's performance in total time and distance for completion, and acceleration
Study: NCT04215705

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus block versus peritubal local infiltration
Description: Quadratus lumborum block III versus peritubal local infiltration in patients undergoing Percutaneous Nephrolithotomy operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus block versus peritubal local infiltration
Description: Quadratus lumborum block III versus peritubal local infiltration in patients undergoing Percutaneous Nephrolithotomy operation
Study: NCT00777023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Extended-Release (G-ER) 1200 mg
Description: G-ER 1200 mg daily dosage given as two 600-mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Extended-Release (G-ER) 1800 mg
Description: G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
Study: NCT00085293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting dose 6 mg/m\^2 intravenously over 1 hour every day for 5 successive days for 2 weeks (10 doses), with possible second course.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine I 131
Description: Undergo thyrotropin-alfa stimulated radioactive iodine scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant thyrotropin alfa
Description: Undergo thyrotropin-alfa stimulated radioactive iodine scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F 18
Description: Optional correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography
Description: Optional correlative studies
Study: NCT01180634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aeroquin
Description: Inhalation Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation Solution
Study: NCT01564394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Classes will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. The classes will be led by a trained Qigong instructor and consist of postures, movements, deep breathing techniques and meditation. It will include eccentrically-biased Qigong movements with an emphasis on weight shifting and posture control. The continuous body movements coupled with progressively diminishing base of support, dynamic challenge to balance, and concentration on body positions requiring eccentric muscle activity should improve the levels of fatigue and quality of life in older prostate cancer survivors.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Non-aerobic stretching
Description: The non-aerobic stretching classes will serve as an attention control. They will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. They will be led by an Huntsman Cancer Institute (HCI) fitness specialist and will consist of light stretching exercises; while avoiding a focus on meditation.
Study: NCT01441297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: BIBF 1120 200mg bid, PO, daily until PD
Study: NCT02901379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Description: Subject will be given atorvastatin 80mg for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Subjects will be give atorvastatin 10mg as part of standard therapy in hospital
Study: NCT04304066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-WL12 PET or 68Ga-WL12 PET
Description: WL12, labeled with PET radio-nuclide ( Ga-68 or F-18)will be used as a molecular imaging tracer for PET/CT scanning
Study: NCT03505151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 (C-13/N-15)
Description: i.v solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet
Study: NCT02986451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle.
Study: NCT03690791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MediCabilis CBD Oil
Description: 50 mg of CBD: \<2mg of THC in one ml. The cannabis oil consists of CBD extract in MCT oil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: Placebo will contain only hemp seed oil.
Study: NCT03190239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m2 qm
Study: NCT02199873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIX 1 XX - single rising dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01098968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: School intervention program specifically designed to increase health-related physical fitness

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: School intervention program specifically designed to increase health-related physical fitness
Study: NCT00686751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.
Study: NCT06673420

Intervention type: OTHER
Intervention: No Interventions
Description: This is an observational study
Study: NCT00572143

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ca coli follow-up by GP
Description: patients randomized to follow up by GP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ca coli follow-up by GP
Description: patients randomized to follow up by GP
Study: NCT02038374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsies
Study: NCT04603378

Intervention type: OTHER
Group type: OTHER
Intervention: KB195
Description: KB195 is a novel glycan

Intervention type: OTHER
Group type: OTHER
Intervention: Polydextrose
Description: Polydextrose is an oligosaccharide

Intervention type: OTHER
Group type: OTHER
Intervention: Pullulan
Description: Pullulan is an oligosaccharide

Intervention type: OTHER
Group type: OTHER
Intervention: Maltodextrin
Description: Maltodextrin is a digestible carbohydrate
Study: NCT02604121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orcellex® Rovers brush
Description: transepithelial brushing
Study: NCT03690960

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrospun TAP nanofibers
Description: electrospun TAP loaded nanofibers containing modified triple antibiotic paste of clindamycin , ciprofloxacin and metronidazole by electrospinning process will be placed in the root canals. The access cavity will be sealed with temporary filling material

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified TAP paste
Description: modified TAP paste will be prepared by mixing equal proportions of CIP, MET and CLIN then placed inside the root canal, access cavity will be sealed with temporary filling
Study: NCT04066088

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered same times as GXR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR)
Description: The starting dose for all subjects will be 1 mg per day. If the medication is well-tolerated, the dose can be raised to 2 mg until day 28 and increased to 3mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed; the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8, the study will be unblinded and subjects will continue treatment for 8 more weeks.
Study: NCT01773408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781 MBP
Description: Participants will receive RO5503781 tablets daily (current formulation) containing microprecipitated bulk powder (MBP) at a starting dose of 400 milligrams (mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781 MBP
Description: Participants will receive RO5503781 tablets daily (current formulation) containing microprecipitated bulk powder (MBP) at a starting dose of 400 milligrams (mg).
Study: NCT00611156

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Added to a bruch meal
Study: NCT01773408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781 MBP
Description: Participants will receive RO5503781 tablets daily (current formulation) containing microprecipitated bulk powder (MBP) at a starting dose of 400 milligrams (mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781 SDP
Description: Participants will receive RO5503781 tablets daily (new optimized formulation) containing spray-dried powder (SDP) at recommended dose(s) for development from Phase 1b to Phase 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Idarubicin will be administered as per standard clinical practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Daunorubicin will be administered as per standard clinical practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m\^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m\^2 IV infusion daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m\^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m\^2 IV infusion daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m\^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m\^2 IV infusion daily.
Study: NCT02057835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 691751
Description: Placebo to BI 691751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751 high dose
Description: BI 691751 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751 middle dose
Description: BI 691751 middle dose
Study: NCT03474835

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ISCHEMIC HEART DISEASE diagnostic
Description: ISCHEMIC HEART DISEASE diagnostic
Study: NCT01535300

Intervention type: PROCEDURE
Intervention: Ultrasonography of the trachea
Description: Ultrasonographic measurement of the minimal transverse tracheal diameter
Study: NCT00130442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88 and dacarbazine
Description: 190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine or DTIC
Description: intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle
Study: NCT02112448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous infusion
Description: Continuous morphine/midazolam and 'as needed' doses. Will receive scheduled acetaminophen and ketorolac.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: as needed dosing
Description: morphine and midazolam as needed. Will receive scheduled acetaminophen and ketorolac..

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen will be given every 4 hours for a total of 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen will be given every 4 hours for a total of 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac
Description: Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac
Description: Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.
Study: NCT04486274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MOSE
Description: After each pass, the stylet will be introduced into the needle, the material will be released onto a smear slide, and a macroscopic on-site quality evaluation (MOSE) of the specimen will be performed by the endoscopist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MOSE
Description: After each pass, the stylet will be introduced into the needle, the material will be released onto a smear slide, and a macroscopic on-site quality evaluation (MOSE) of the specimen will be performed by the endoscopist.
Study: NCT00828373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the lidocaine Arm this regimen corresponds to 1.5 mg kg-1 lidocaine bolus injection and 2 mg kg-1 h-1 lidocaine continuous infusion. The infusion will be stopped after complete recovery from the neuromuscular block.
Study: NCT03545516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Injection of bupivacaine into the surgical incision prior to its closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Injection of bupivacaine into the surgical incision prior to its closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Injection of dexmedetomidine ( an adjuvant) into the surgical incision prior to its closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of a placebo into the surgical wound
Study: NCT04086043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Denervation
Description: multi-electrode catheter-based endovascular denervation